Archived Monthly Oncology Tumor Boards: Use of Checkpoint Inhibitors for Treatment of Metastatic Colorectal Cancer
It is difficult for clinicians to stay current with the evolving treatment options for colorectal cancer, and they can benefit from education about these therapies.
Category
  • Colorectal Cancer
Format
  • Recorded Webcast
Credits
  • 1.00 AAPA Category 1 CME credit
  • 1.00 ACPE contact hours
  • 1.00 AMA PRA Category 1 Credit™
  • 1.00 ANCC contact hours
  • 1.00 CCM clock hours
  • 1.00 Participation
Updates in the Treatment of Metastatic Colorectal Cancer
Targeted therapy approaches for mCRC continue to evolve as new data helps define how to best improve outcomes. Decisions regarding treatment for patients with mCRC require that clinicians be familiar with existing and new targeted therapies as well as the most effective and tolerable combination regimens.
Category
  • Colorectal Cancer
  • Rectal Cancer
Format
  • Recorded Webcast
Credits
  • 1.00 AAPA Category 1 CME credit
  • 1.00 ACPE contact hours
  • 1.00 AMA PRA Category 1 Credit™
  • 1.00 ANCC contact hours
  • 1.00 Participation
Archived Monthly Oncology Tumor Boards: Treatment of Deficient Mismatch Repair or Microsatellite Instability-High (dMMR/MSI-H) Colorectal Cancer
As the clinical understanding of biomarkers in colorectal cancer has deepened, it has become increasingly clear that deficient mismatch repair or microsatellite instability-high (dMMR/MSI-H) colorectal cancer should be treated differently from proficient mismatch repair or microsatellite stable (pMMR/MSS) disease in order to reach the best possible outcomes for patients.
Category
  • Colorectal Cancer
Format
  • Recorded Webcast
Credits
  • 1.00 AAPA Category 1 CME credit
  • 1.00 ACPE contact hours
  • 1.00 AMA PRA Category 1 Credit™
  • 1.00 ANCC contact hours
  • 1.00 CCM clock hours
  • 1.00 Participation